Genmab A/S (NASDAQ:GMAB) Shares Sold by Hardman Johnston Global Advisors LLC

Hardman Johnston Global Advisors LLC lowered its stake in shares of Genmab A/S (NASDAQ:GMAB) by 5.9% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 214,472 shares of the company’s stock after selling 13,487 shares during the quarter. Hardman Johnston Global Advisors LLC’s holdings in Genmab A/S were worth $4,476,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds have also recently added to or reduced their stakes in GMAB. Two Sigma Advisers LP boosted its holdings in Genmab A/S by 84.1% in the third quarter. Two Sigma Advisers LP now owns 615,100 shares of the company’s stock worth $14,996,000 after purchasing an additional 280,900 shares during the period. ABC Arbitrage SA acquired a new position in Genmab A/S in the fourth quarter worth $3,692,000. Y Intercept Hong Kong Ltd boosted its holdings in Genmab A/S by 371.0% in the fourth quarter. Y Intercept Hong Kong Ltd now owns 73,696 shares of the company’s stock worth $1,538,000 after purchasing an additional 58,048 shares during the period. Natixis Advisors LLC boosted its holdings in Genmab A/S by 29.8% in the third quarter. Natixis Advisors LLC now owns 206,563 shares of the company’s stock worth $5,036,000 after purchasing an additional 47,437 shares during the period. Finally, Mirae Asset Global Investments Co. Ltd. boosted its holdings in Genmab A/S by 229.9% in the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 49,727 shares of the company’s stock worth $1,033,000 after purchasing an additional 34,652 shares during the period. Institutional investors and hedge funds own 7.07% of the company’s stock.

Genmab A/S Stock Down 0.4 %

Shares of NASDAQ GMAB opened at $22.34 on Monday. Genmab A/S has a fifty-two week low of $18.64 and a fifty-two week high of $31.88. The firm’s 50-day simple moving average is $20.72 and its 200 day simple moving average is $22.89. The stock has a market cap of $14.78 billion, a P/E ratio of 12.84, a P/E/G ratio of 2.65 and a beta of 0.96.

Genmab A/S (NASDAQ:GMAB) last issued its quarterly earnings data on Wednesday, February 12th. The company reported $0.57 earnings per share for the quarter, beating analysts’ consensus estimates of $0.28 by $0.29. Genmab A/S had a net margin of 36.30% and a return on equity of 16.78%. On average, sell-side analysts anticipate that Genmab A/S will post 1.45 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

A number of research firms have issued reports on GMAB. BMO Capital Markets reiterated an “outperform” rating and issued a $48.00 target price (up from $46.00) on shares of Genmab A/S in a research note on Friday, November 8th. Leerink Partners upgraded Genmab A/S from a “market perform” rating to an “outperform” rating and set a $27.00 target price on the stock in a research note on Thursday, February 13th. Leerink Partnrs upgraded Genmab A/S from a “hold” rating to a “strong-buy” rating in a research note on Thursday, February 13th. BNP Paribas upgraded Genmab A/S from a “strong sell” rating to a “hold” rating in a research note on Tuesday, February 11th. Finally, Sanford C. Bernstein upgraded Genmab A/S from a “strong sell” rating to a “hold” rating in a research note on Friday, December 20th. Four equities research analysts have rated the stock with a hold rating, seven have given a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and an average price target of $42.17.

Genmab A/S Company Profile

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.